Last reviewed · How we verify
NCT07487064: TARGET
Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study
NA trial testing Aliya Pulsed Electric Field (PEF) in Lung Cancer in 25 participants. Currently enrolling.
31 January 2027
Quick facts
| Lead sponsor | Galvanize Therapeutics, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 13 March 2026 |
| Primary completion | 31 January 2027 |
| Estimated completion | 28 February 2027 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Aliya Pulsed Electric Field (PEF)
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Galvanize Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, single-arm, non-randomized, single-center, open-label, treat and resect study following patients through surgical resection. The study is designed to evaluate the safety and feasibility of the Aliya EX System for the ablation of pulmonary lesions using pulsed electric field (PEF) energy delivery. The study is intended for adult patients with suspected or confirmed pulmonary malignant lesion(s) ≥1.5 cm to ≤4 cm whom are surgical candidates and have not received treatment for the index tumor in the last two years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07487064
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
- NCT07367581 — Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer · NA · recruiting
Other Galvanize Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05851430 — Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry · recruiting
- NCT05890872 — Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer · NA · completed
- NCT05583188 — Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC · Phase 4 · terminated
- NCT04773275 — A Clinical Evaluation of the Aliya™ System in Late Stage Cancer · NA · terminated
- NCT04732520 — Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07487064 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Galvanize Therapeutics, Inc.
- Last refreshed: 23 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07487064.